Use of omalizumab as adjuvant therapy in AIT for respiratory allergies
| Reference | Study type | Allergen | Patients | Main results/aims |
|---|---|---|---|---|
| Kuehr et al. [8], 2002 | RCT, DBPC | Grass, birch | 221 | Combined therapy outperforms either component alone in terms of the symptom score and the rescue medication score. |
| Casale et al. [9], 2006 | RCT, DBPC | Ragweed | 159 | Omalizumab before treatment showed a five-fold reduction in the risk of rush anaphylaxis associated with SCIT. The use of combination therapy was associated with a decrease in the intensity of symptoms compared to SCIT alone. |
| Kopp et al. [10], 2009 | RCT, DBPC | Grass | 140 | Combination therapy led to a decrease in daily symptom scores, an improvement in QoL and in the management of rhinoconjunctivitis and asthma. |
| Massanari et al. [11], 2010 | RCT, DBPC | Mite, cat, dog | 225 | Omalizumab before treatment correlated with a decreased occurrence of systemic reactions and an increased chance of reaching the maintenance SCIT dose. |
| Stelmach et al. [12], 2015 | RCT, DBPC | Mite, moulds | 7 | Consecutive combination therapy resulted in the reduction of exacerbation frequency and hospitalizations. Significant decrease in the utilization of steroids was observed. |
| Valdesoiro-Navarrete et al. [13], 2022 | Retrospective study | Mite, Alternaria, and pollens | 29 | Combination therapy resulted in a significant improvement of asthma control score (CAN questionnaire) and forced expiratory volume in one second (FEV1), following a year of treatment. |
RCT: randomized controlled trial; SCIT: subcutaneous immunotherapy; QoL: quality of life